MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, EVMN had $11,767K increase in cash & cash equivalents over the period. -$59,873K in free cash flow.

Cash Flow Overview

Change in Cash
$11,767K
Free Cash flow
-$59,873K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
Net loss
-40,597
Stock-based compensation expense
1,660
Accretion of discount on short-term investments
1,184
Depreciation and amortization
1,063
Change in fair value of convertible preferred stock forward
8,928
Prepaid expenses and other assets
1,998
Accounts payable
-4,688
Accrued liabilities
-1,479
Operating lease liabilities
-591
Deferred revenue
-3,000
Net cash used in operating activities
-59,742
Purchases of short-term investments
38,775
Maturities of short-term investments
46,500
Purchase of property and equipment
131
Net cash provided by investing activities
7,594
Proceeds from issuance of convertible preferred stock, net of issuance costs
65,228
Proceeds from exercise of stock options
6
Payment of deferred offering costs
874
Principal payments of finance lease liability
287
Principal payments of financing obligation
158
Net cash provided by (used in) financing activities
63,915
Net increase (decrease) in cash, cash equivalents and restricted cash
11,767
Cash and cash equivalents at beginning of period
16,463
Cash and cash equivalents at end of period
28,230
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Evommune, Inc. (EVMN)

Evommune, Inc. (EVMN)